Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 59% Improvement Relative Risk HCQ for COVID-19  Pinato et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 890 patients in multiple countries Lower mortality with HCQ (p=0.0001) c19hcq.org Pinato et al., Cancer Discovery, August 2020 Favors HCQ Favors control

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

Pinato et al., Cancer Discovery, doi:10.1158/2159-8290.CD-20-0773
Aug 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Restrospective 890 cancer patients with COVID-19, adjusted mortality HR for HCQ/CQ 0.41, p<0.0001.
Confirmed SARS-CoV-2 infection was required, which may help focus on more severe cases. Analysis with Cox proportional hazard model. Potential unmeasured confounders.
risk of death, 59.0% lower, HR 0.41, p < 0.001, treatment 30 of 182 (16.5%), control 181 of 446 (40.6%), NNT 4.1.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pinato et al., 18 Aug 2020, retrospective, multiple countries, peer-reviewed, 64 authors.
This PaperHCQAll
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
David J Pinato, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher C T Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Elia Seguí, Federica Biello, Daniele Generali, Salvatore Grisanti, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Nadia Harbeck, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Anna Carbó, Riccardo Bruna, Sarah Benafif, Andrea Marrari, Rachel Wuerstlein, M Carmen Carmona-Garcia, Neha Chopra, Carlo Tondini, Oriol Mirallas, Valeria Tovazzi, Marta Betti, Salvatore Provenzano, Vittoria Fotia, Claudia Andrea Cruz, Alessia Dalla Pria, Francesca D'avanzo, Joanne S Evans, Nadia Saoudi-Gonzalez, Eudald Felip, Myria Galazi, Isabel Garcia-Fructuoso, Alvin J X Lee, Thomas Newsom-Davis, Andrea Patriarca, David García-Illescas, Roxana Reyes, Palma Dileo, Rachel Sharkey, Yien Ning Sophia Wong, Daniela Ferrante, Javier Marco-Hernández, Anna Sureda, Clara Maluquer, Isabel Ruiz-Camps, Gianluca Gaidano, Lorenza Rimassa, Lorenzo Chiudinelli, Macarena Izuzquiza, Alba Cabirta, Michela Franchi, Armando Santoro, Aleix Prat, Josep Tabernero, Alessandra Gennari, Gian Carlo Avanzi, Mattia Bellan, Luigi Mario Castello, Maria Martinez, Meritxell Mollà, Mario Pirisi, Lorenza Scotti, Judith Swallow
Cancer Discovery, doi:10.1158/2159-8290.cd-20-0773
The SARS-CoV-2 pandemic signifi cantly affected oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncologic features to severity and mortality from COVID-19 and little guidance as to the role of anticancer and anti-COVID-19 therapy in this population. In a multicenter study of 890 patients with cancer with confi rmed COVID-19, we demonstrated a worsening gradient of mortality from breast cancer to hematologic malignancies and showed that male gender, older age, and number of comorbidities identify a subset of patients with signifi cantly worse mortality rates from COVID-19. Provision of chemotherapy, targeted therapy, or immunotherapy did not worsen mortality. Exposure to antimalarials was associated with improved mortality rates independent of baseline prognostic factors. This study highlights the clinical utility of demographic factors for individualized risk stratifi cation of patients and supports further research into emerging anti-COVID-19 therapeutics in SARS-CoV-2-infected patients with cancer. SIGNIFICANCE: In this observational study of 890 patients with cancer diagnosed with SARS-CoV-2, mortality was 33.6% and predicted by male gender, age ≥65, and comorbidity burden. Delivery of cancer therapy was not detrimental to severity or mortality from COVID-19. These patients should be the focus of shielding efforts during the SARS-CoV-2 pandemic. Cancer Research.
References
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19 -preliminary report, N Engl J Med
Bhatraju, Ghassemieh, Nichols, Kim, Jerome et al., Covid-19 in critically ill patients in the Seattle region -case series, N Engl J Med
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med
Corman, Landt, Kaiser, Molenkamp, Meijer et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill
Dai, Liu, Liu, Zhou, Li et al., Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak, Cancer Discov
Ferrari, Motta, Strollo, Banfi, Locatelli, Routine blood tests as a potential diagnostic tool for COVID-19, Clin Chem Lab Med
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Hanna, Evans, Booth, Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic, Nat Rev Clin Oncol
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Lake, What we know so far: COVID-19 current clinical knowledge and research, Clin Med
Lewis, Between Scylla and Charybdis -Oncologic decision making in the time of Covid-19, N Engl J Med
Liang, Guan, Chen, Li, Xu, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol
Lilly, Exelixis; Fibrogen; Incyte; Ipsen; Merck Sharp & Dohme, Roche, Astrazeneca, Bayer et al., ), and non-financial support from Ipsen (Travel expenses) outside the submitted work. A. Prat reports personal fees from Roche, personal fees from Novartis, personal fees from Pfizer, personal fees from Daiichi Sankyo, personal fees from Oncolytics Biotech, personal fees from AstraZeneca, personal fees from NanoString Technologies, and personal fees from Seattle Genetics outside the submitted work
Lilly, Gilead; Incyte; Ipsen; Roche, Lecture fees
Lu, Zhao, Li, Niu, Yang et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet
Luo, Rizvi, Egger, Preeshagul, Wolchok et al., Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers, Cancer Discov
Mehra, Desai, Ruschitzka, Patel, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet
Mehra, Desai, Ruschitzka, Patel, RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet
Montopoli, Zumerle, Vettor, Rugge, Zorzi et al., Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n = 4532), Ann Oncol
Rome, Avorn, Drug evaluation during the Covid-19 pandemic, N Engl J Med
Safdar, Armstrong, Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects, Clin Infect Dis
Salvi, Patankar, Emerging pharmacotherapies for COVID-19, Biomed Pharmacother
Sehatzadeh, Cardiopulmonary resuscitation in patients with terminal illness: an evidence-based analysis, Ont Health Technol Assess Ser
Ueda, Martins, Hendrie, Mcdonnell, Crews et al., Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal, J Natl Compr Canc Netw
Van De Haar, Hoes, Coles, Seamon, Frohling et al., Caring for patients with cancer in the COVID-19 era, Nat Med
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China
Wu, Chen, Cai, Xia, Zhou et al., Risk Factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China, JAMA Intern Med
Zhang, Zhu, Xie, Wang, Wang et al., Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China, Ann Oncol
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit